Sponsors (10)
The bill increases targeted outreach, research coordination, and trial inclusion to address racial and age-related disparities in endometrial cancer, but its modest specified funding, funding uncertainty, and risks around messaging and trial logistics may limit how effectively those benefits reach the women most affected.
African‑American and other racial/ethnic minority women will receive targeted public information about their higher endometrial cancer risk and treatment options, increasing awareness and encouraging earlier care-seeking.
NIH-funded research coordination and increased research attention will accelerate study of endometrial cancer causes, diagnostics, and treatments, potentially improving care for patients with the disease.
Clinical trials will be more inclusive by requiring African‑American women to be enrolled in proportion to incidence, improving the equity and generalizability of research findings.
The NIH appropriation is limited to $1 million per year (FY2026–2028), which is likely insufficient to support large-scale research, trial recruitment, or sustained interventions.
CDC funding described as “such sums as may be necessary” creates budgetary uncertainty and could lead to variable program scope and uneven implementation year-to-year.
Requiring proportional representation of African‑American women in NIH trials could slow enrollment, complicate logistics, or raise trial costs if recruitment resources are inadequate.
Based on analysis of 3 sections of legislative text.
Directs NIH to expand and coordinate endometrial cancer research and require proportional African‑American trial representation; directs CDC to run targeted public education; authorizes FY2026–2028 funding.
Introduced September 9, 2025 by David Scott · Last progress September 9, 2025
Directs the NIH to expand and coordinate research on endometrial cancer, improve communication about racial disparities in diagnosis and outcomes, and require that African‑American women be represented in NIH‑supported endometrial cancer clinical trials in proportion to incidence. Directs the CDC to develop and distribute public education materials about endometrial cancer—targeting African‑American women—and authorizes funding for NIH and CDC activities for fiscal years 2026–2028.